Handbook of Genetic Counseling/18q Deletion Syndrome

< Handbook of Genetic Counseling

18q Deletion Syndrome

Genetic Etiology

Incidence and Carrier Frequency

Clinical Features

This syndrome is variable in its severity. The symptoms usually correlate with the size of the deletion.

Key features:

Age of onset, natural history, life span

Testing

Diagnosis is confirmed by chromosome studies

Surveillance, management, and treatment options

Patients should be monitored by endocrinology, audiology, ophthalmology, genetics, neurology, orthopedics, immunology, physical therapy, occupational therapy, speech therapy, and Early Intervention.

Recent research has uncovered potential treatment for short stature and dysmyelination caused by 18q-. Growth hormone treatment has been shown to potentially increase IQ in children with 18q-. A 2005 study performed by Cody et al. showed that over a treatment period of 37 months an average nIQ increase of 17 pts, and an increase in height standard deviation score of 1.7. All but one of the children who tested within measureable range (>50) to the nonverbal IQ test had, at the end of the study, an IQ within normal range (i.e., >70).

Psychosocial issues

Guilt, fear, anxiety, anger, sadness, and disbelief are common emotions associated with this diagnosis. Parents may feel overwhelmed. Financial concerns, issues affecting family dynamics, and what care may be needed for the individual with 18q- are all things that should be addressed with parents.

References

Notes

The information in this outline was last updated in 2002.

This article is issued from Wikibooks. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.